Mouse Models of Retinal Neovascularization in the MICRON Literature
About the MICRON Research Literature
These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.
All publication counts and figures reflect the complete indexed research collection.
Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.
Understanding Retinal Neovascularization
Retinal neovascularization is new-vessel growth arising from the retinal circulation. In proliferative ischemic retinopathies such as diabetic retinopathy, retinal vein occlusion and retinopathy of prematurity, non-perfusion and tissue hypoxia are major drivers, with VEGF among the mediators linking ischemia to the vascular response.
Where the new vessels go varies and matters:
- They may cross the inner limiting membrane onto the retinal surface and into the vitreous
- Extend outward through the retina toward the subretinal space
Vessels that arise instead from the choroid, or from the limbal circulation into the cornea, arise from different vascular beds and in different anatomical and disease contexts, even though angiogenic mediators such as VEGF can be shared.
What threatens sight in people is largely what these vessels then do, leaking, bleeding into the vitreous, and drawing fibrovascular tissue that can contract and detach the retina. Leakage is imageable in the living eye, while new vessels that do not leak can be missed by that measurement.
Retinal Neovascularization in Experimental Research
Animal preparations make the vascular response available for repeated imaging and histology, together with its response to an intervention. In induced models the initiating exposure is placed at a known time; genetic models instead provide a reproducible genotype-dependent course whose onset and severity have to be characterized rather than assumed.
Whether a given preparation goes on to the fibrovascular and tractional stage is a property of that preparation and has to be established rather than inferred from the presence of new vessels.
The retinas differ in ways that bound what can be reproduced:
- Mouse, rat and macaque retinas are holangiotic, carrying retinal vessels across the retina as the human retina does
- The rabbit retina is merangiotic, its retinal vessels confined to the medullary rays with the remainder of the retina supplied from the choroid
- Macaques have a macula where mice, rats and rabbits do not
Mouse Models of Retinal Neovascularization
The mouse carries most of this work.
Transgenic and knockout lines allow a pathway to be removed or overexpressed, and cost, availability, short generation time and a large body of background data reinforce the choice.
A genetic manipulation constrains rather than isolates a mechanism: developmental compensation and pleiotropy remain possible.
Published MICRON Research: Retinal Neovascularization in Mice
This page lists 75 papers from the MICRON literature, published 2013 to 2026, that study retinal neovascularization in mice.
Of these publications:
- 74 studies used mice as the primary retinal neovascularization disease model.
- 1 study used healthy animals to assess pharmacokinetics, drug delivery, or tolerability.
Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published retinal neovascularization research.
Which imaging and experimental techniques are used in these studies?
| Technique | Papers |
|---|---|
| Fundus Fluorescein Angiography | 55 |
| Intravitreal Injection / Delivery | 41 |
| Electroretinography | 34 |
| Optical Coherence Tomography | 33 |
| Laser Photocoagulation Models | 25 |
| Topical Ophthalmic Drug Delivery | 14 |
| AAV-Mediated Ocular Gene Delivery | 6 |
| CRISPR-Based Ocular Gene Editing | 1 |
| Ocular Implants / Sustained Release | 1 |
| Optogenetics (Vision Restoration) | 1 |
| Optokinetic / Optomotor Response | 1 |
Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.
Capabilities and Limitations of Imaging Techniques
A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications. The others appear in the table and not here: Optogenetics (Vision Restoration).
Fundus Fluorescein Angiography
Fundus fluorescein angiography uses an injected fluorescent dye to visualize blood flow through the retinal and choroidal circulation. Sequential images show how vessels fill, identify areas of reduced or absent perfusion, and reveal dye leakage associated with vascular abnormalities.
This technique is particularly useful for evaluating vascular perfusion, blood-retinal barrier integrity, and abnormal vessel growth. Fluorescein angiography primarily shows dye distribution rather than the surrounding retinal tissue. It provides a two-dimensional (en face) view in which vessels at different depths may overlap. Cross-sectional and cellular structural details require other imaging methods, such as optical coherence tomography (OCT) or optical coherence tomography angiography (OCT-A). Vascular abnormalities that do not affect dye filling or produce leakage may also remain undetected.
Intravitreal Injection / Delivery
Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.
Electroretinography
Records the retina's electrical response to light, giving component-sensitive information about outer- and inner-retinal function. It measures function directly, which no structural method does. Full-field ERG sums across the whole retina, so a small lesion can leave the trace unchanged; focal and multifocal variants trade signal amplitude for spatial resolution.
Optical Coherence Tomography
Optical coherence tomography provides high-resolution, cross-sectional images of ocular tissues in the living eye, allowing researchers to visualize structures at different depths. OCT is particularly useful for measuring tissue thickness, identifying structural abnormalities, and assessing the location and extent of tissue changes.
As a non-invasive imaging technique, OCT enables repeated measurements in the same eye over time, supporting longitudinal studies of disease progression and treatment response. Although OCT provides detailed structural information, it does not directly measure cellular activity or visual function. Tissue that appears structurally normal may still have functional abnormalities, making OCT a valuable companion to functional assessments such as electroretinography (ERG).
Laser Photocoagulation Models
A laser lesion provokes a reproducible, quantifiable injury at a known time and place. Wavelength, power, duration, spot size, pulse mode, focus and lesion location together determine the injury produced, allowing laser exposure to be configured for different experimental endpoints. It is an induced injury, not the disease: it produces a lesion directly, bypassing the process that gives rise to comparable damage in patients.
Topical Ophthalmic Drug Delivery
A compound applied as drops to the ocular surface. It is non-invasive and repeatable, so it supports frequent dosing without a procedure for each dose. What the route has to establish depends on the target: for an ocular-surface target, residence time and penetration into the surface tissue are the main barriers; for an intraocular anterior-segment target, the compound must cross ocular-surface and corneal or conjunctival barriers and reach an intraocular concentration sufficient for the experiment; for a posterior-segment target, additional ocular barriers separate the surface from the target and posterior-segment exposure is harder to establish.
AAV-Mediated Ocular Gene Delivery
An adeno-associated viral vector delivers genetic material to ocular cells, and a single administration can support long-lived transgene expression. That persistence is useful for gene augmentation and sustained therapeutic-protein expression; AAV can also deliver gene-silencing or genome-editing cargo, where long-lived expression of the editing machinery may be unnecessary or undesirable. Capsid and route of delivery jointly determine which cells are reached, so different delivery routes and vector designs give different distributions.
CRISPR-Based Ocular Gene Editing
Uses a programmable genome-editing system to alter DNA at an endogenous locus rather than adding a separate replacement copy. Depending on the editor and design, it can disrupt, correct or install a sequence, either therapeutically or to create an experimental model. Once a genomic sequence change is established, the edit itself cannot be withdrawn like a dose; where the edit is present from conception, the resulting phenotype also reflects its effects throughout development. Off-target sequence changes are a separate question that structural imaging does not establish.
Ocular Implants / Sustained Release
A sustained-release system holds a compound in or on the eye and lets it out gradually, so exposure is maintained from one placement rather than from a series of doses. The class spans polymer and non-polymer solid depots, injectable and particulate carriers, and reservoir devices; the release period belongs to the platform and not to the route, and runs from days to years. What the approach is for is to separate the dosing interval from the procedure interval, holding exposure at the target for as long as the question runs, whether that is the few weeks of a short-lived model or the span of a lifelong disease, without an intervention for each dose. What it gives up is control after placement. The release profile has to be measured rather than assumed, altering or ending delivery may require a further procedure, biodegradable systems behave differently from removable ones, and the carrier sits in contact with ocular tissue, so how the eye tolerates it is part of the result and not a precondition of it.
Optokinetic / Optomotor Response
Measures a reflexive head or eye movement tracking a moving pattern, giving a rapid, training-free behavioral estimate of spatial vision and contrast sensitivity in an animal that cannot report them. It is driven largely by reflex circuitry and reports on the visual pathway as a whole, so a deficit it detects still has to be localized by a structural or electrophysiological method, or separated from cortical processing by an operant task.
Which MICRON systems and add-ons appear?
| Instrument | Papers |
|---|---|
| MICRON IV | 39 |
| MICRON III | 35 |
| Image-Guided OCT | 16 |
| Image-Guided Laser | 12 |
| Ganzfeld ERG System | 3 |
| Insight Software | 3 |
| Image-Guided Focal ERG | 2 |
| MICRON II | 2 |
| MICRON 5 | 1 |
Which strains and genetic lines are used?
| Strain | Papers | Reported as |
|---|---|---|
| C57BL/6J | 44 | C57/BL6J, C57BL/6 J, C57BL/6j, C57BL6/J |
| C57BL/6 | 14 | |
| 129S6 | 2 | |
| B6.129P2-Cbstm1Unc/J | 2 | |
| B6.Cg-Crb1rd8/Pjn | 1 | |
| BALB/c | 1 | |
| C57BL/6 (Ins2Akita) | 1 | |
| C57BL/6N | 1 | |
| C57Bl/6/129V | 1 | |
| JR5558 | 1 | |
| NRV2 (JR5558) | 1 | |
| Townes | 1 | |
| Vldlr−/− | 1 |
Which other species appear alongside?
| Species | Papers |
|---|---|
| Rabbit | 6 |
| Cynomolgus Macaque | 2 |
| Rat | 2 |
| Swine / Domestic Pig | 1 |
What other conditions are recorded on the same papers?
| Disease | Papers |
|---|---|
| Age-Related Macular Degeneration (Wet/Neovascular) | 32 |
| Choroidal Neovascularization | 31 |
| Retinopathy of Prematurity | 30 |
| Age-Related Macular Degeneration (General) | 29 |
| Retinal Degeneration (General) | 19 |
| Diabetic Retinopathy | 11 |
| Retinal Detachment | 8 |
| Retinal Pigment Epithelium Dysfunction | 8 |
| Age-Related Macular Degeneration (Dry/Atrophic) | 5 |
| Retinal Hemorrhage | 5 |
| Diabetes Mellitus, Type 1 | 3 |
| Diabetic Retinal Neurodegeneration | 3 |
| Retinal Dysplasia | 3 |
| Cone Dystrophy / Cone-Rod Dystrophy | 2 |
| Retinal Vein Occlusion (RVO) | 2 |
| Retinitis Pigmentosa (RP) | 2 |
| Uveitis (General) | 2 |
| Corneal Neovascularization | 1 |
| Corneal Wound Healing | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Endotoxin-Induced Uveitis (EIU) | 1 |
| Epiretinal Membrane | 1 |
| Experimental Autoimmune Uveoretinitis (EAU) | 1 |
| Leber Congenital Amaurosis (LCA) | 1 |
| Retinal Drusen | 1 |
| Retinal Ganglion Cell Degeneration | 1 |
| Retinoblastoma | 1 |
| Sickle Cell Retinopathy | 1 |
| Stargardt Disease | 1 |
Retinal neovascularization is new-vessel growth arising from the retinal circulation. In proliferative ischemic retinopathies such as diabetic retinopathy, retinal vein occlusion and retinopathy of prematurity, non-perfusion and tissue hypoxia are major drivers, with VEGF among the mediators linking ischemia to the vascular response. Where the new vessels go varies and matters: they may cross the inner limiting membrane onto the retinal surface and into the vitreous, or extend outward through the retina toward the subretinal space, and vessels that arise instead from the choroid, or from the limbal circulation into the cornea, arise from different vascular beds and in different anatomical and disease contexts, even though angiogenic mediators such as VEGF can be shared. What threatens sight in people is largely what these vessels then do, leaking, bleeding into the vitreous, and drawing fibrovascular tissue that can contract and detach the retina; leakage is imageable in the living eye, while new vessels that do not leak can be missed by that measurement. Animal preparations make the vascular response available for repeated imaging and histology, together with its response to an intervention. In induced models the initiating exposure is placed at a known time; genetic models instead provide a reproducible genotype-dependent course whose onset and severity have to be characterized rather than assumed. Whether a given preparation goes on to the fibrovascular and tractional stage is a property of that preparation and has to be established rather than inferred from the presence of new vessels. The retinas differ in ways that bound what can be reproduced: mouse, rat and macaque retinas are holangiotic, carrying retinal vessels across the retina as the human retina does, whereas the rabbit retina is merangiotic, its retinal vessels confined to the medullary rays with the remainder of the retina supplied from the choroid; and macaques have a macula where mice, rats and rabbits do not.
Which MICRON configurations appear in this work?
Configurations recorded in these papers, and the techniques recorded alongside them.
| MICRON configuration | Papers | Most frequent techniques recorded alongside |
|---|---|---|
| MICRON IV | 39 | Fundus Fluorescein Angiography (29), Intravitreal Injection / Delivery (23), Electroretinography (18) |
| MICRON III | 35 | Fundus Fluorescein Angiography (25), Intravitreal Injection / Delivery (17), Electroretinography (15) |
| Image-Guided OCT | 16 | Optical Coherence Tomography (15), Fundus Fluorescein Angiography (14), Electroretinography (11) |
| Image-Guided Laser | 12 | Fundus Fluorescein Angiography (9), Intravitreal Injection / Delivery (8), Laser Photocoagulation Models (7) |
| Ganzfeld ERG System | 3 | Electroretinography (3), Intravitreal Injection / Delivery (3), Optical Coherence Tomography (3) |
| Insight Software | 3 | Electroretinography (3), Fundus Fluorescein Angiography (3), Optical Coherence Tomography (3) |
| Image-Guided Focal ERG | 2 | Intravitreal Injection / Delivery (2), Electroretinography (1), Fundus Fluorescein Angiography (1) |
| MICRON II | 2 | Fundus Fluorescein Angiography (2), Optical Coherence Tomography (2), Electroretinography (1) |
| MICRON 5 | 1 | Electroretinography (1), Optokinetic / Optomotor Response (1), Topical Ophthalmic Drug Delivery (1) |
The papers
| Year | Title | Journal | Role of focal species | MICRON products | Links |
|---|---|---|---|---|---|
| 2026 | Inhibition of pathological angiogenesis in oxygen-induced retinopathy by arginine depletion with ADI-PEG20. | Experimental Eye Research | Disease model | MICRON IV | DOI · reSEARCH |
| 2026 | FRZB-induced anti-angiogenic effect via Caveolin-1-mediated TGFβ signalling. | Nature Communications | Disease model | Image-Guided Laser, MICRON IV | DOI · reSEARCH |
| 2026 | Circulating natural killer cells are phenotypically and functionally altered in age-related macular degeneration. | Cell Reports. Medicine | Disease model | Image-Guided Laser, MICRON IV | DOI · reSEARCH |
| 2026 | Efficacy of anti-VEGF single-chain variable fragment AAV-based gene therapy in a laser-induced choroidal neovascularisation mouse model. | Molecular Therapy. Advances | Disease model | Image-Guided Focal ERG, Image-Guided Laser, MICRON III | DOI · reSEARCH |
| 2026 | Extraocular delivery of bioswitchable tri-miR-22-loaded tetrahedral DNA nanostructures for intraocular neovascular and neurodegenerative repair. | Signal Transduction and Targeted Therapy | Disease model | Image-Guided Laser, Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2025 | Intravitreal Bevacizumab nanoparticles ameliorates retinal vasculopathy in an in vivo mouse model of retinopathy of prematurity. | Pediatric Research | Disease model | MICRON IV | DOI · reSEARCH |
| 2025 | The Ercc1-/Δ mouse model of XFE progeroid syndrome undergoes accelerated retinal degeneration. | Aging Cell | Disease model | MICRON 5 | DOI · reSEARCH |
| 2025 | Sustained release of a novel non-fibrate PPARα agonist from microparticles for neuroprotection in murine models of age-related macular degeneration. | Journal of Controlled Release | Disease model | MICRON IV | DOI · reSEARCH |
| 2025 | Pten Loss Triggers Progressive Photoreceptor Degeneration in an mTORC1-Independent Manner. | Investigative Ophthalmology & Visual Science | Disease model | MICRON IV | DOI · reSEARCH |
| 2025 | Exploitation of enhanced prime editing for blocking aberrant angiogenesis. | Journal of Advanced Research | Disease model | Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2025 | Targeted siRNA Delivery Against RUNX1 Via tFNA: Inhibiting Retinal Neovascularization and Restoring Vessels Through Dll4/Notch1 Signaling. | Investigative Ophthalmology & Visual Science | Disease model | Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2025 | PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases. | Nature Communications | Disease model | Image-Guided Laser, Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2025 | Pericyte Expression of VEGF-A Minimally Impacts Ocular Vascular Development and Neovascularization. | Cells | Disease model | MICRON III | DOI · reSEARCH |
| 2025 | Ref-1 is overexpressed in neovascular eye disease and targetable with a novel inhibitor. | Angiogenesis | Disease model | Image-Guided Laser, Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2025 | AI Quantification of Vascular Lesions in Mouse Fundus Fluorescein Angiography. | Translational Vision Science & Technology | Disease model | Image-Guided Laser, MICRON IV | DOI · reSEARCH |
| 2025 | HIF1 activity in photoreceptors drives type 3 neovascularization and retinal atrophy in a new mouse model of age-related macular degeneration. | Cell Death & Disease | Disease model | Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2025 | Restoring compromised blood-retina-barrier integrity with Netrin-1 overexpression. | Cellular and Molecular Life Sciences | Disease model | Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2024 | pH-Responsive polymer boosts cytosolic siRNA release for retinal neovascularization therapy. | Acta Pharmaceutica Sinica. B | Disease model | MICRON IV | DOI · reSEARCH |
| 2024 | SOCS3 regulates pathological retinal angiogenesis through modulating SPP1 expression in microglia and macrophages. | Molecular Therapy | Disease model | Image-Guided Laser, MICRON IV | DOI · reSEARCH |
| 2024 | Receptor-Interacting Protein Kinase-3 Expression Impacts Ocular Vascular Development and Pathological Neovascularization. | Cells | Disease model | MICRON III | DOI · reSEARCH |
| 2024 | α-Klotho prevents diabetic retinopathy by reversing the senescence of macrophages. | Cell Communication and Signaling | Disease model | Ganzfeld ERG System, MICRON IV | DOI · reSEARCH |
| 2024 | A Multifunctional Nanodrug Co-Delivering VEGF-siRNA and Dexamethasone for Synergistic Therapy in Ocular Neovascular Diseases. | International Journal of Nanomedicine | Disease model | MICRON IV | DOI · reSEARCH |
| 2024 | Photoreceptors inhibit pathological retinal angiogenesis through transcriptional regulation of Adam17 via c-Fos. | Angiogenesis | Disease model | Image-Guided OCT, Insight Software, MICRON IV | DOI · reSEARCH |
| 2024 | Therapeutic intervention in neuroinflammation for neovascular ocular diseases through targeting the cGAS-STING-necroptosis pathway. | Journal of Neuroinflammation | Disease model | MICRON IV | DOI · reSEARCH |
| 2024 | Epithelial Membrane Protein 2 (EMP2) Blockade Attenuates Pathological Neovascularization in Murine Oxygen-Induced Retinopathy. | Investigative Ophthalmology & Visual Science | Disease model | MICRON II | DOI · reSEARCH |
| 2023 | Leverage of nuclease-deficient CasX for preventing pathological angiogenesis. | Molecular Therapy. Nucleic Acids | Disease model | MICRON III | DOI · reSEARCH |
| 2023 | AAV2-antiVEGFscFv gene therapy for retinal neovascularization. | Molecular Therapy. Methods & Clinical Development | Disease model | MICRON III | DOI · reSEARCH |
| 2023 | Enhanced therapeutic effect of PEDF-loaded mesenchymal stem cell-derived small extracellular vesicles against oxygen-induced retinopathy through increased stability and penetrability of PEDF. | Journal of Nanobiotechnology | Disease model | Ganzfeld ERG System, MICRON IV | DOI · reSEARCH |
| 2022 | Identification of Arhgef12 and Prkci as genetic modifiers of retinal dysplasia in the Crb1rd8 mouse model. | PLoS Genetics | Disease model | MICRON IV | DOI · reSEARCH |
| 2022 | A Splicing Mutation in Slc4a5 Results in Retinal Detachment and Retinal Pigment Epithelium Dysfunction. | International Journal of Molecular Sciences | Disease model | MICRON III, MICRON IV | DOI · reSEARCH |
| 2021 | AAV-Mediated Expression of Human VEGF, TNF-α, and IL-6 Induces Retinal Pathology in Mice. | Translational Vision Science & Technology | Disease model | MICRON IV | DOI · reSEARCH |
| 2021 | PSF functions as a repressor of hypoxia-induced angiogenesis by promoting mitochondrial function. | Cell Communication and Signaling | Disease model | MICRON III | DOI · reSEARCH |
| 2021 | Quantification of retinal blood leakage in fundus fluorescein angiography in a retinal angiogenesis model. | Scientific Reports | Disease model | MICRON IV | DOI · reSEARCH |
| 2021 | Exacerbation of AMD Phenotype in Lasered CNV Murine Model by Dysbiotic Oral Pathogens. | Antioxidants | Disease model | Image-Guided OCT, MICRON III, MICRON IV | DOI · reSEARCH |
| 2020 | miR-106b suppresses pathological retinal angiogenesis. | Aging | Disease model | MICRON IV | DOI · reSEARCH |
| 2020 | Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates pathological retinal angiogenesis by suppressing vascular endothelial growth factor-induced Arf6 activation. | Experimental & Molecular Medicine | Disease model | Image-Guided Laser, MICRON IV | DOI · reSEARCH |
| 2020 | Ferrochelatase regulates retinal neovascularization. | FASEB Journal | Disease model | Image-Guided OCT, MICRON III | DOI · reSEARCH |
| 2020 | Retbindin: A riboflavin Binding Protein, Is Critical for Photoreceptor Homeostasis and Survival in Models of Retinal Degeneration. | International Journal of Molecular Sciences | Disease model | MICRON IV | DOI · reSEARCH |
| 2020 | Elimination of a Retinal Riboflavin Binding Protein Exacerbates Degeneration in a Model of Cone-Rod Dystrophy. | Investigative Ophthalmology & Visual Science | Disease model | MICRON IV | DOI · reSEARCH |
| 2020 | Effects of high-fat diet and Apoe deficiency on retinal structure and function in mice. | Scientific Reports | Disease model | Image-Guided OCT, Insight Software, MICRON IV | DOI · reSEARCH |
| 2019 | Rb1/Rbl1/Vhl loss induces mouse subretinal angiomatous proliferation and hemangioblastoma. | JCI Insight | Disease model | MICRON III | DOI · reSEARCH |
| 2019 | A collagen IV-derived peptide disrupts α5β1 integrin and potentiates Ang2/Tie2 signaling. | JCI Insight | Disease model | MICRON III | DOI · reSEARCH |
| 2019 | Intravitreal Delivery of VEGF-A165-loaded PLGA Microparticles Reduces Retinal Vaso-Obliteration in an In Vivo Mouse Model of Retinopathy of Prematurity. | Current Eye Research | Disease model | MICRON IV | DOI · reSEARCH |
| 2019 | Anisotropic poly(lactic-co-glycolic acid) microparticles enable sustained release of a peptide for long-term inhibition of ocular neovascularization. | Acta Biomaterialia | Disease model | MICRON III | DOI · reSEARCH |
| 2018 | AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration. | Molecular Therapy | Disease model | MICRON III | DOI · reSEARCH |
| 2018 | Mousetap, a Novel Technique to Collect Uncontaminated Vitreous or Aqueous and Expand Usefulness of Mouse Models. | Scientific Reports | Disease model | MICRON III | DOI · reSEARCH |
| 2018 | Re-programming immunosurveillance in persistent non-infectious ocular inflammation. | Progress in Retinal and Eye Research | Disease model | Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2018 | The NLRP3 Inflammasome May Contribute to Pathologic Neovascularization in the Advanced Stages of Diabetic Retinopathy. | Scientific Reports | Disease model | Image-Guided OCT, Insight Software, MICRON IV | DOI · reSEARCH |
| 2018 | Targeting Hif1a rescues cone degeneration and prevents subretinal neovascularization in a model of chronic hypoxia. | Molecular Neurodegeneration | Disease model | MICRON IV | DOI · reSEARCH |
| 2017 | Bim expression in endothelial cells and pericytes is essential for regression of the fetal ocular vasculature. | PLoS ONE | Disease model | MICRON III | DOI · reSEARCH |
| 2017 | Sema3f Protects Against Subretinal Neovascularization In Vivo. | EBioMedicine | Disease model | MICRON IV | DOI · reSEARCH |
| 2017 | Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration. | Investigative Ophthalmology & Visual Science | Disease model | MICRON III | DOI · reSEARCH |
| 2017 | Vitamin D receptor expression is essential during retinal vascular development and attenuation of neovascularization by 1, 25(OH)2D3. | PLoS ONE | Disease model | MICRON III | DOI · reSEARCH |
| 2017 | Neuropilin 1 Involvement in Choroidal and Retinal Neovascularisation. | PLoS ONE | Disease model | Image-Guided Laser, MICRON III | DOI · reSEARCH |
| 2017 | Generation and characterization of ABBV642, a dual variable domain immunoglobulin molecule (DVD-Ig) that potently neutralizes VEGF and PDGF-BB and is designed for the treatment of exudative age-related macular degeneration. | mAbs | Disease model | MICRON III | DOI · reSEARCH |
| 2016 | Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. | EMBO Molecular Medicine | Disease model | Ganzfeld ERG System, MICRON III | DOI · reSEARCH |
| 2016 | Oral Monomethyl Fumarate Therapy Ameliorates Retinopathy in a Humanized Mouse Model of Sickle Cell Disease. | Antioxidants & Redox Signaling | Disease model | MICRON III | DOI · reSEARCH |
| 2016 | Mthfr as a modifier of the retinal phenotype of Crb1(rd8/rd8) mice. | Experimental Eye Research | Disease model | MICRON III | DOI · reSEARCH |
| 2016 | A hypomorphic mutation of the gamma-1 adaptin gene (Ap1g1) causes inner ear, retina, thyroid, and testes abnormalities in mice. | Mammalian Genome | Disease model | Image-Guided OCT, MICRON III | DOI · reSEARCH |
| 2016 | Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis. | EBioMedicine | Disease model | Image-Guided Laser, MICRON IV | DOI · reSEARCH |
| 2016 | Col4a1 mutations cause progressive retinal neovascular defects and retinopathy. | Scientific Reports | Disease model | Image-Guided OCT, MICRON III | DOI · reSEARCH |
| 2015 | Safety and angiogenic effects of systemic gene delivery of a modified erythropoietin. | Gene Therapy | Healthy PK, delivery or tolerability | MICRON III | DOI · reSEARCH |
| 2015 | Anti-angiogenic effect of metformin in mouse oxygen-induced retinopathy is mediated by reducing levels of the vascular endothelial growth factor receptor Flk-1. | PLoS ONE | Disease model | MICRON III | DOI · reSEARCH |
| 2015 | Pigment epithelium-derived factor inhibits retinal microvascular dysfunction induced by 12/15-lipoxygenase-derived eicosanoids. | Biochimica et Biophysica Acta | Disease model | MICRON III | DOI · reSEARCH |
| 2014 | Effects of anti-VEGF treatment on the recovery of the developing retina following oxygen-induced retinopathy. | Investigative Ophthalmology & Visual Science | Disease model | Image-Guided Focal ERG, MICRON III | DOI · reSEARCH |
| 2014 | Alterations of retinal vasculature in cystathionine-β-synthase heterozygous mice: a model of mild to moderate hyperhomocysteinemia. | The American Journal of Pathology | Disease model | MICRON III | DOI · reSEARCH |
| 2014 | Endothelial TWIST1 promotes pathological ocular angiogenesis. | Investigative Ophthalmology & Visual Science | Disease model | Image-Guided Laser, MICRON IV | DOI · reSEARCH |
| 2014 | Characterization of a spontaneous retinal neovascular mouse model. | PLoS ONE | Disease model | Image-Guided OCT, MICRON III | DOI · reSEARCH |
| 2014 | Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A. | Angiogenesis | Disease model | MICRON III | DOI · reSEARCH |
| 2014 | Sustained inhibition of neovascularization in vldlr-/- mice following intravitreal injection of cerium oxide nanoparticles and the role of the ASK1-P38/JNK-NF-κB pathway. | Biomaterials | Disease model | MICRON III | DOI · reSEARCH |
| 2014 | Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization. | PLoS ONE | Disease model | MICRON IV | DOI · reSEARCH |
| 2013 | Alterations of retinal vasculature in cystathionine-Beta-synthase mutant mice, a model of hyperhomocysteinemia. | Investigative Ophthalmology & Visual Science | Disease model | MICRON III | DOI · reSEARCH |
| 2013 | Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. | eLife | Disease model | MICRON II | DOI · reSEARCH |
| 2013 | Sustained delivery of a HIF-1 antagonist for ocular neovascularization. | Journal of Controlled Release | Disease model | MICRON III | DOI · reSEARCH |
| 2013 | Retinal angiogenesis in the Ins2(Akita) mouse model of diabetic retinopathy. | Investigative Ophthalmology & Visual Science | Disease model | MICRON III | DOI · reSEARCH |
Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.